CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 198 enrolled
Drug / intervention
Nitroglycerindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02961946
NCT02961946Phase 4Completed
CompareCT.gov

Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality

Massachusetts General Hospital·interventional·Posted Nov 11, 2016·Updated Sep 17, 2019

In Brief

A Phase 4 clinical trial evaluating Nitroglycerin for Coronary Artery Disease. Completed, enrolled 198 participants across 1 site.

Detailed Summary

To evaluate image quality of coronary CT angiography (cCTA) after sublingual and transdermal administration of Nitroglycerin. Aim of this prospective research study is to investigate equivalence on image quality after sublingual or transdermal Nitroglycerin administration (H0). Furthermore, the feasibility of transdermal Nitroglycerin administration will be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 11, 2016
Enrollment StartMar 15, 2017
Primary CompletionOct 31, 2017
Study CompletionAug 2, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.6 years ago

Interventions

Nitroglycerindrug

Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.